文献速递复苏、休克与脓毒症消化、代谢与肾脏急症重症综合管理与镇静镇痛

重症中性粒细胞减少患者的坏死性软组织感染:法国多中心回顾性队列研究

Necrotizing soft tissue infections in critically ill neutropenic patients: a French multicentre retrospective cohort study.
PubMed 文献 · Ann Intensive Care · 2023-04-28
一句话结论ICU中性粒细胞减少的坏死性软组织感染患者病死率57.9%,明显高于非中性粒细胞减少者的28.5%,粒细胞集落刺激因子(G-CSF)使用与住院生存相关。

该法国18个ICU的回顾性多中心队列研究纳入2011至2021年因坏死性软组织感染(NSTI)入住ICU且诊断时合并中性粒细胞减少的患者76例,与非中性粒细胞减少的NSTI患者165例比较。中性粒细胞减少组更年轻(54±14岁 vs 60±13岁,p=0.002),下肢NSTI更少(44.7% vs 70.9%,p<0.001),腹会阴部NSTI更多(43.4% vs 18.8%,p<0.001),最常见分离微生物为肠杆菌目和非发酵革兰阴性菌。中性粒细胞减少组住院病死率显著更高(57.9% vs 28.5%,p<0.001)。G-CSF给药与较低住院死亡风险相关:单因素Cox HR=0.43(95%CI 0.23-0.82,p=0.010),多因素Cox校正HR=0.46(95%CI 0.22-0.94,p=0.033),重叠倾向评分加权后OR=0.25(95%CI 0.09-0.68,p=0.006)。

要点

  • 中性粒细胞减少的NSTI患者住院病死率57.9%,显著高于非中性粒细胞减少者的28.5%(p<0.001)。
  • 中性粒细胞减少组更年轻(54±14 vs 60±13岁,p=0.002),腹会阴部NSTI更多(43.4% vs 18.8%,p<0.001),下肢NSTI更少(44.7% vs 70.9%,p<0.001)。
  • 中性粒细胞减少患者最常见分离微生物为肠杆菌目和非发酵革兰阴性菌。
  • G-CSF给药与较低住院死亡风险相关:单因素Cox HR=0.43(95%CI 0.23-0.82,p=0.010),多因素校正HR=0.46(95%CI 0.22-0.94,p=0.033),倾向评分加权OR=0.25(95%CI 0.09-0.68,p=0.006)。

适用人群与场景

  • 2011至2021年法国18个ICU收治的、诊断NSTI时合并中性粒细胞减少的成人患者(76例),并与同期非中性粒细胞减少的NSTI患者(165例)比较。

研究设计与关键结果

  • 研究类型:法国18个ICU的回顾性多中心队列研究,纳入76例中性粒细胞减少的NSTI患者与165例非中性粒细胞减少的NSTI患者。
  • 中性粒细胞减少组vs非中性粒细胞减少组:年龄54±14岁 vs 60±13岁(p=0.002);下肢NSTI 44.7% vs 70.9%(p<0.001);腹会阴部NSTI 43.4% vs 18.8%(p<0.001)。
  • 中性粒细胞减少患者最常见分离微生物为肠杆菌目和非发酵革兰阴性菌。
  • 住院病死率:中性粒细胞减少组57.9% vs 非中性粒细胞减少组28.5%(p<0.001)。
  • G-CSF给药与住院死亡风险降低相关:单因素Cox HR=0.43(95%CI 0.23-0.82,p=0.010);多因素Cox校正HR=0.46(95%CI 0.22-0.94,p=0.033);重叠倾向评分加权OR=0.25(95%CI 0.09-0.68,p=0.006)。

证据类型、等级与局限

  • 证据类型:回顾性多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于ICU中诊断NSTI且合并中性粒细胞减少的患者,应认识到其临床特征(更年轻、腹会阴部NSTI更多、下肢NSTI更少)和微生物学(肠杆菌目和非发酵革兰阴性菌为主)不同于非中性粒细胞减少患者,且住院病死率更高(57.9% vs 28.5%)。
  • 作者认为G-CSF给药与住院生存相关,但该关联来自回顾性队列,原文未给出G-CSF的剂量、给药途径或疗程。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Necrotizing soft tissue infections (NSTIs) are rare life-threatening bacterial infections. Few data are available regarding neutropenic patients with NSTIs. Our objectives were to describe the characteristics and management of neutropenic patients with NSTIs in intensive care units (ICUs). We conducted a retrospective multicentre cohort study in 18 ICUs between 2011 and 2021. Patients admitted with NSTIs and concomitant neutropenia at diagnosis were included and compared to non-neutropenic patients with NSTIs. The relationship between therapeutic interventions and outcomes was assessed using Cox regression and propensity score matching.

RESULTS: 76 neutropenic patients were included and compared to 165 non-neutropenic patients. Neutropenic patients were younger (54 ± 14 vs 60 ± 13 years, p = 0.002) and had less lower limb (44.7% vs 70.9%, p < 0.001) and more abdomino-perineal NSTIs (43.4% vs 18.8%, p < 0.001). Enterobacterales and non-fermenting gram-negative bacteria were the most frequently isolated microorganisms in neutropenic patients. In-hospital mortality was significantly higher in neutropenic than in non-neutropenic patients (57.9% vs 28.5%, p < 0.001). Granulocyte colony-stimulating factor (G-CSF) administration was associated with a lower risk of in-hospital mortality in univariable Cox (hazard ratio (HR) = 0.43 95% confidence interval (CI) [0.23-0.82], p = 0.010) and multivariable Cox (adjusted HR = 0.46 95% CI [0.22-0.94], p = 0.033) analyses and after overlap propensity score weighting (odds ratio = 0.25 95% CI [0.09; 0.68], p = 0.006).

CONCLUSIONS: Critically ill neutropenic patients with NSTIs present different clinical and microbiological characteristics and are associated with a higher hospital mortality than non-neutropenic patients. G-CSF administration was associated with hospital survival.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Arrestier R, Chaba A, Mabrouki A, et al. Necrotizing soft tissue infections in critically ill neutropenic patients: a French multicentre retrospective cohort study. Ann Intensive Care. 2023. PMID: 37115415. doi:10.1186/s13613-023-01125-w

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。